CBIO — CRESCENT BIOPHARMA, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1253689 ·
Last close
$13.04
Market Cap
$507.20M
52W High
$27.41
52W Low
$8.72
ADV30
268,813
Next earnings
—
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 3,117,000 — -39,907,000 -37,726,000 299,503,000 289,357,000 25,224,000
Jun 2026 0 — -26,364,000 -24,837,000 182,758,000 171,593,000 19,503,000
Mar 2026 1,039,000 — -24,729,000 -23,283,000 199,130,000 189,163,000 15,283,000
Dec 2025 10,844,000 — -91,492,000 -92,397,000 240,293,000 213,192,000 37,281,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-72,679,000
Investing CF
$-79,169,000
Financing CF
$170,797,000
CapEx
$-80,939,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.72
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-219,929,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-163,124,000
Pretax Income TTM
$-163,124,000
Interest Exp TTM
$0
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$15,000,000
EBITDA
$-184,011,008
Free Cash Flow
—
Enterprise Value
$269,787,456
Total Cash
$289,356,992
Total Debt
$2,458,000
Shares Out
38,895,442
Trailing EPS
$-7.63
Book Value
$4.77
ROE
—
ROA
—
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 10,844,000 -152,632,000 -153,942,000 240,293,000 37,281,000 203,012,000 -71,532,000
Dec 2024 — — — 35,617,000 51,096,000 -15,479,000 —

TTM Snapshot

Revenues TTM
$11,883,000
NetIncome TTM
$-177,928,264
OpCashFlow TTM
—
Assets (Latest)
$182,758,000
Forward EPS
$-2.63

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $12.40 · call volume: 17 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
EVO Evotec SE $525.98M $1.48 —
HELP Helus Pharma Inc. $526.03M $7.20 —
CAPR CAPRICOR THERAPEUTICS, INC. $488.98M $8.41 —
GYRE GYRE THERAPEUTICS, INC. $488.23M $4.56 —
MNPR Monopar Therapeutics $481.56M $71.06 —

News headlines (Yahoo Finance, 1h cache)

Crescent Biopharma: Q3 Earnings Snapshot
2026-11-12 21:47 · Yahoo
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 21:15 · Yahoo
Crescent Biopharma Announces Grants of Inducement Awards
2026-11-03 21:15 · Yahoo
Crescent Biopharma to Present at November Investor Conferences
2026-11-02 12:30 · Yahoo
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis
2026-10-15 20:15 · Yahoo
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
2026-10-05 11:30 · Yahoo
Crescent Biopharma to Present at September Investor Conferences
2026-09-03 11:30 · Yahoo
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-07-16 20:01 · Yahoo
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-15 01:45 · Yahoo
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-14 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.